Results from two large-scale efficacy trials found that injectable cabotegravir (CAB-LA), given every two months, was effective as a form of pre-exposure prophylaxis (PrEP) in preventing HIV in gay men and other men who have sex with men, transgender women who have sex with men, and cisgender women. CAB-LA was developed by ViiV Healthcare and is currently used in HIV treatment. It was approved by the US Food and Drug Administration (FDA) as the first form of injectable PrEP in December 2021. This document focuses on CAB-LA for prevention, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy.
Advocates’ Primer on Injectable Cabotegravir for PrEP: Trials, Approvals, Rollout and More
COMPASS
Since 2017, the Coalition to Build Momentum, Power, Strategy and Solidarity has broken new ground in transnational HIV activism that’s grounded in rigorous analysis, fearless tactics and collaboration across geographies. We’re winning commitments and changes that will drive epidemic control. Read on to see what the future of AIDS activism looks like.
Five “P”s to Watch
HIV vaccine research is making the search for a COVID-19 vaccine faster, safer and more inclusive. The global COVID-19 response evolves by the day—seemingly, even, by the minute—as the world has watched the tally of experimental diagnostics, therapeutics and vaccines tick up into the hundreds. If researchers achieve their goal of making the search for a COVID-19 vaccine the fastest vaccine development effort in history, much of that success will be due to the research knowledge, vaccine platforms, trial networks and community engagement models created through HIV vaccine research.
Understanding COVID-19 Mathematical Models
This brief provides information on mathematical modeling for the COVID-19 pandemic.
Advocates Call for Ethical Research for COVID-19 Solutions
More than 260 organizations and individuals have joined an Advocates Call for Ethical Research for COVID-19 Solutions. Read the letter reiterating the essential role of ethical research, and the need to move forward based on facts and evidence, and help us carry this message forward!
Applying Lessons from Family Planning to HIV Prevention Product Introduction
An analysis of lessons and data from family planning in sub-Saharan Africa to better inform introduction of HIV prevention products and integration of HIV prevention into family planning settings.
Integration of HIV Prevention and Sexual Reproductive Health Services in Kenya
Findings from an assessment of HIV prevention and SRH integration in Kenya, conducted in collaboration with the Ministry of Health, comprised of site visits to health facilities, key informant interviews, civil society dialogues and a policy review.
HIV & Sexual and Reproductive Health Integration
Compilation of top learnings on and approaches to implementing HIV/SRH integration in sub-Saharan Africa, drawn from literature reviews, qualitative interviews, and an analysis of policy requirements for PrEP and family planning providers.
Exploring Integration of Family Planning and HIV Services
A literature review to identify existing knowledge on barriers and enablers to the integration of HIV and family planning services in sub-Saharan Africa, in order to understand the feasibility of providing existing and new HIV prevention options and services in family planning settings.
Frequently Asked Questions (FAQ) – Index Testing
Index testing, a PEPFAR initiative that tracks the contacts of people who test positive for HIV, has potential benefits when done ethically. But index testing is presently being aggressively implemented in ways that cause harm, increase risk of violence and undermine people’s rights to consent, confidentiality and safety. Changes must be made to protect individuals and foster community trust in their healthcare system. For activists and advocates attending PEPFAR in-country retreats, this FAQ provides background and advocacy priorities.